Jennifer Taylor-Cousar
Concepts (353)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 136 | 2026 | 1164 | 23.490 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 82 | 2026 | 373 | 15.590 |
Why?
| | Quinolones | 43 | 2026 | 204 | 9.790 |
Why?
| | Aminophenols | 54 | 2026 | 204 | 9.590 |
Why?
| | Benzodioxoles | 39 | 2026 | 164 | 7.230 |
Why?
| | Chloride Channel Agonists | 35 | 2026 | 111 | 5.620 |
Why?
| | Indoles | 32 | 2026 | 511 | 4.610 |
Why?
| | Sinusitis | 12 | 2025 | 221 | 3.710 |
Why?
| | Pyridines | 26 | 2026 | 610 | 3.160 |
Why?
| | Pyrrolidines | 23 | 2026 | 127 | 2.960 |
Why?
| | Pyrazoles | 28 | 2026 | 517 | 2.920 |
Why?
| | Rhinitis | 10 | 2025 | 159 | 2.910 |
Why?
| | Olfaction Disorders | 9 | 2026 | 74 | 2.400 |
Why?
| | Drug Combinations | 31 | 2026 | 400 | 2.320 |
Why?
| | Aminopyridines | 7 | 2026 | 128 | 2.000 |
Why?
| | Pregnancy Complications | 7 | 2026 | 609 | 1.820 |
Why?
| | Mutation | 34 | 2024 | 4093 | 1.820 |
Why?
| | Membrane Transport Modulators | 3 | 2020 | 7 | 1.750 |
Why?
| | Fetal Therapies | 2 | 2026 | 48 | 1.740 |
Why?
| | Pongo pygmaeus | 3 | 2024 | 7 | 1.720 |
Why?
| | Ape Diseases | 3 | 2024 | 7 | 1.490 |
Why?
| | Reproductive Health | 9 | 2024 | 94 | 1.300 |
Why?
| | Humans | 145 | 2026 | 146342 | 1.270 |
Why?
| | Azithromycin | 7 | 2021 | 101 | 1.230 |
Why?
| | Quality of Life | 19 | 2026 | 3200 | 1.220 |
Why?
| | Pregnancy Outcome | 7 | 2026 | 503 | 1.200 |
Why?
| | Pregnancy | 23 | 2026 | 7230 | 1.200 |
Why?
| | Adult | 73 | 2026 | 41087 | 1.110 |
Why?
| | Quinolines | 11 | 2026 | 191 | 1.080 |
Why?
| | Respiratory System Agents | 2 | 2020 | 22 | 1.050 |
Why?
| | Sexual Health | 6 | 2025 | 67 | 1.040 |
Why?
| | Parents | 5 | 2024 | 1394 | 1.040 |
Why?
| | Reproductive Techniques, Assisted | 3 | 2025 | 48 | 1.030 |
Why?
| | Female | 86 | 2026 | 79499 | 1.010 |
Why?
| | Paranasal Sinuses | 5 | 2024 | 77 | 0.920 |
Why?
| | Sweat | 11 | 2026 | 52 | 0.910 |
Why?
| | Chronic Disease | 16 | 2026 | 1827 | 0.870 |
Why?
| | Pseudomonas Infections | 9 | 2024 | 229 | 0.840 |
Why?
| | Drug Approval | 3 | 2024 | 94 | 0.830 |
Why?
| | Smell | 5 | 2026 | 129 | 0.810 |
Why?
| | Fetal Diseases | 1 | 2026 | 192 | 0.810 |
Why?
| | Pregnancy Rate | 3 | 2021 | 83 | 0.800 |
Why?
| | Respiratory Mucosa | 2 | 2025 | 323 | 0.800 |
Why?
| | Pongo | 2 | 2021 | 7 | 0.790 |
Why?
| | Anti-Bacterial Agents | 12 | 2024 | 1942 | 0.790 |
Why?
| | Treatment Outcome | 27 | 2026 | 11821 | 0.770 |
Why?
| | Genetic Therapy | 5 | 2026 | 303 | 0.770 |
Why?
| | Prospective Studies | 19 | 2026 | 8123 | 0.730 |
Why?
| | Male | 66 | 2026 | 73396 | 0.710 |
Why?
| | Lung | 10 | 2026 | 4122 | 0.680 |
Why?
| | Chlorides | 9 | 2026 | 138 | 0.680 |
Why?
| | Aerosols | 2 | 2026 | 146 | 0.670 |
Why?
| | Lung Transplantation | 1 | 2024 | 326 | 0.660 |
Why?
| | Young Adult | 33 | 2026 | 14330 | 0.660 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 1101 | 0.660 |
Why?
| | Glucose Intolerance | 2 | 2025 | 142 | 0.650 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 21 | 0.650 |
Why?
| | Sputum | 6 | 2026 | 302 | 0.630 |
Why?
| | Compassionate Use Trials | 1 | 2019 | 7 | 0.610 |
Why?
| | Forced Expiratory Volume | 12 | 2026 | 451 | 0.590 |
Why?
| | Fertility | 3 | 2025 | 174 | 0.570 |
Why?
| | Transcriptome | 1 | 2025 | 1068 | 0.560 |
Why?
| | Precision Medicine | 2 | 2021 | 462 | 0.560 |
Why?
| | Pseudomonas aeruginosa | 9 | 2022 | 392 | 0.550 |
Why?
| | Glucose Tolerance Test | 3 | 2026 | 360 | 0.550 |
Why?
| | Adolescent | 34 | 2026 | 22557 | 0.550 |
Why?
| | Breast Feeding | 3 | 2025 | 447 | 0.540 |
Why?
| | Drug Monitoring | 6 | 2020 | 399 | 0.510 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 266 | 0.510 |
Why?
| | Contraceptives, Oral, Hormonal | 3 | 2026 | 30 | 0.510 |
Why?
| | Child | 25 | 2026 | 22693 | 0.500 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 28 | 0.500 |
Why?
| | Rifampin | 1 | 2017 | 80 | 0.480 |
Why?
| | Leukocyte Elastase | 2 | 2026 | 75 | 0.480 |
Why?
| | Pongo abelii | 1 | 2016 | 1 | 0.470 |
Why?
| | Biomedical Research | 3 | 2024 | 729 | 0.460 |
Why?
| | Surveys and Questionnaires | 12 | 2026 | 6073 | 0.450 |
Why?
| | Sildenafil Citrate | 2 | 2014 | 60 | 0.440 |
Why?
| | Minimal Clinically Important Difference | 2 | 2026 | 35 | 0.430 |
Why?
| | Bronchiectasis | 1 | 2016 | 115 | 0.420 |
Why?
| | Tobramycin | 5 | 2019 | 63 | 0.410 |
Why?
| | Genotype | 10 | 2026 | 1879 | 0.410 |
Why?
| | Infertility, Male | 2 | 2025 | 69 | 0.410 |
Why?
| | Double-Blind Method | 11 | 2026 | 2070 | 0.390 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2020 | 665 | 0.390 |
Why?
| | Respiratory Function Tests | 6 | 2025 | 543 | 0.360 |
Why?
| | Lactation | 3 | 2022 | 193 | 0.350 |
Why?
| | Contraception Behavior | 2 | 2025 | 108 | 0.340 |
Why?
| | Homozygote | 4 | 2021 | 197 | 0.330 |
Why?
| | Contraception | 2 | 2025 | 170 | 0.320 |
Why?
| | Drug Interactions | 4 | 2020 | 405 | 0.300 |
Why?
| | International Cooperation | 2 | 2020 | 193 | 0.290 |
Why?
| | Respiratory Muscles | 1 | 2009 | 36 | 0.290 |
Why?
| | Hypoventilation | 1 | 2009 | 17 | 0.290 |
Why?
| | Alleles | 8 | 2025 | 907 | 0.290 |
Why?
| | Animals | 13 | 2026 | 38107 | 0.290 |
Why?
| | Blood Glucose | 3 | 2025 | 2360 | 0.270 |
Why?
| | ABO Blood-Group System | 1 | 2009 | 56 | 0.270 |
Why?
| | Parenting | 2 | 2023 | 309 | 0.270 |
Why?
| | Clinical Trials as Topic | 3 | 2025 | 1064 | 0.270 |
Why?
| | Pyrroles | 2 | 2026 | 222 | 0.260 |
Why?
| | Middle Aged | 23 | 2026 | 36619 | 0.260 |
Why?
| | Tomography, X-Ray Computed | 4 | 2022 | 2786 | 0.250 |
Why?
| | Asthma | 3 | 2024 | 1800 | 0.250 |
Why?
| | Needs Assessment | 2 | 2020 | 404 | 0.250 |
Why?
| | Quinuclidines | 1 | 2026 | 11 | 0.230 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 612 | 0.230 |
Why?
| | Sexual Behavior | 3 | 2025 | 490 | 0.230 |
Why?
| | United States | 11 | 2025 | 16136 | 0.230 |
Why?
| | Dependovirus | 1 | 2026 | 78 | 0.230 |
Why?
| | Phenylpropionates | 1 | 2025 | 27 | 0.230 |
Why?
| | Infant, Newborn | 5 | 2026 | 6460 | 0.220 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 133 | 0.220 |
Why?
| | Airway Remodeling | 1 | 2025 | 63 | 0.220 |
Why?
| | Off-Label Use | 1 | 2025 | 50 | 0.220 |
Why?
| | Cough | 1 | 2026 | 123 | 0.220 |
Why?
| | Oligonucleotides, Antisense | 1 | 2025 | 122 | 0.210 |
Why?
| | Endoscopy | 5 | 2026 | 316 | 0.210 |
Why?
| | Biomarkers | 6 | 2026 | 4340 | 0.210 |
Why?
| | Organoids | 1 | 2026 | 143 | 0.200 |
Why?
| | Fertility Preservation | 1 | 2024 | 57 | 0.200 |
Why?
| | Food Preferences | 1 | 2025 | 126 | 0.200 |
Why?
| | Liver Cirrhosis | 1 | 2026 | 278 | 0.200 |
Why?
| | Orphan Drug Production | 1 | 2023 | 5 | 0.200 |
Why?
| | Pregnancy, Unplanned | 2 | 2023 | 48 | 0.200 |
Why?
| | C-Reactive Protein | 2 | 2018 | 429 | 0.190 |
Why?
| | Sexually Transmitted Diseases | 1 | 2025 | 163 | 0.190 |
Why?
| | Patient Selection | 2 | 2019 | 728 | 0.190 |
Why?
| | Intestines | 1 | 2026 | 351 | 0.190 |
Why?
| | Respiratory Tract Diseases | 1 | 2024 | 178 | 0.190 |
Why?
| | Ion Transport | 2 | 2021 | 61 | 0.190 |
Why?
| | Abortion, Spontaneous | 1 | 2023 | 120 | 0.190 |
Why?
| | Body Height | 1 | 2023 | 205 | 0.180 |
Why?
| | Neonatal Screening | 1 | 2024 | 185 | 0.180 |
Why?
| | Puberty | 1 | 2023 | 141 | 0.180 |
Why?
| | Azabicyclo Compounds | 1 | 2021 | 9 | 0.170 |
Why?
| | Epoxide Hydrolases | 1 | 2021 | 13 | 0.170 |
Why?
| | Enzyme Activators | 1 | 2021 | 9 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2022 | 0.170 |
Why?
| | Benzoates | 1 | 2021 | 48 | 0.170 |
Why?
| | Inflammation | 3 | 2026 | 2919 | 0.170 |
Why?
| | Retrospective Studies | 11 | 2026 | 17438 | 0.170 |
Why?
| | Men's Health | 1 | 2020 | 6 | 0.170 |
Why?
| | RNA, Messenger | 3 | 2022 | 2791 | 0.170 |
Why?
| | Cyclopropanes | 3 | 2026 | 83 | 0.160 |
Why?
| | Vascular Stiffness | 1 | 2026 | 488 | 0.160 |
Why?
| | Infertility | 1 | 2021 | 62 | 0.160 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 417 | 0.160 |
Why?
| | Women's Rights | 1 | 2020 | 4 | 0.160 |
Why?
| | Communicable Disease Control | 1 | 2020 | 88 | 0.150 |
Why?
| | Disease Progression | 5 | 2020 | 2867 | 0.150 |
Why?
| | Virulence Factors | 2 | 2014 | 175 | 0.150 |
Why?
| | Aztreonam | 2 | 2016 | 12 | 0.150 |
Why?
| | Cataract | 1 | 2022 | 240 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 2 | 2025 | 881 | 0.150 |
Why?
| | Colistin | 1 | 2019 | 10 | 0.150 |
Why?
| | Neutrophils | 3 | 2016 | 1133 | 0.150 |
Why?
| | Pilot Projects | 3 | 2026 | 1888 | 0.150 |
Why?
| | Medication Therapy Management | 1 | 2020 | 73 | 0.150 |
Why?
| | Epithelial Cells | 3 | 2026 | 1119 | 0.140 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2025 | 1408 | 0.140 |
Why?
| | Sexism | 1 | 2020 | 70 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2024 | 5439 | 0.140 |
Why?
| | Receptors, Interleukin-8B | 1 | 2018 | 29 | 0.140 |
Why?
| | Health Status | 1 | 2023 | 827 | 0.130 |
Why?
| | Research Design | 1 | 2024 | 1143 | 0.130 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2921 | 0.130 |
Why?
| | Administration, Oral | 1 | 2020 | 872 | 0.130 |
Why?
| | Pyrimidines | 1 | 2021 | 532 | 0.130 |
Why?
| | Mental Health | 1 | 2024 | 779 | 0.130 |
Why?
| | Insulin Resistance | 1 | 2026 | 1247 | 0.130 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.130 |
Why?
| | Patient Reported Outcome Measures | 1 | 2022 | 516 | 0.130 |
Why?
| | HEK293 Cells | 1 | 2020 | 750 | 0.130 |
Why?
| | Pregnancy, High-Risk | 1 | 2017 | 13 | 0.130 |
Why?
| | Leukocytes | 1 | 2018 | 301 | 0.120 |
Why?
| | Risk Assessment | 3 | 2021 | 3712 | 0.120 |
Why?
| | Biological Availability | 1 | 2017 | 146 | 0.120 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 67 | 0.120 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 403 | 0.120 |
Why?
| | Research | 1 | 2020 | 421 | 0.120 |
Why?
| | Risk Factors | 5 | 2026 | 10921 | 0.120 |
Why?
| | Longitudinal Studies | 1 | 2024 | 3017 | 0.120 |
Why?
| | Risk Adjustment | 1 | 2017 | 86 | 0.120 |
Why?
| | Prognosis | 2 | 2022 | 4351 | 0.120 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 253 | 0.110 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1792 | 0.110 |
Why?
| | Albuterol | 1 | 2016 | 76 | 0.110 |
Why?
| | Recovery of Function | 1 | 2020 | 725 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2017 | 176 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 486 | 0.110 |
Why?
| | Health Services Accessibility | 2 | 2024 | 1107 | 0.110 |
Why?
| | Interferons | 1 | 2016 | 186 | 0.110 |
Why?
| | Attitude of Health Personnel | 1 | 2023 | 1219 | 0.110 |
Why?
| | Diabetes Complications | 1 | 2016 | 219 | 0.110 |
Why?
| | Bronchodilator Agents | 1 | 2016 | 186 | 0.110 |
Why?
| | Machine Learning | 1 | 2020 | 594 | 0.110 |
Why?
| | Staphylococcal Infections | 1 | 2019 | 397 | 0.110 |
Why?
| | Child, Preschool | 3 | 2024 | 11913 | 0.100 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2014 | 41 | 0.100 |
Why?
| | Metalloproteases | 1 | 2014 | 42 | 0.100 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 410 | 0.100 |
Why?
| | Quorum Sensing | 1 | 2014 | 80 | 0.100 |
Why?
| | Exercise | 1 | 2026 | 2213 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 2488 | 0.100 |
Why?
| | Body Mass Index | 2 | 2023 | 2458 | 0.100 |
Why?
| | Preconception Care | 2 | 2025 | 50 | 0.100 |
Why?
| | Administration, Inhalation | 3 | 2022 | 567 | 0.100 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 55 | 0.090 |
Why?
| | Neutrophil Activation | 1 | 2013 | 84 | 0.090 |
Why?
| | Condoms | 2 | 2025 | 99 | 0.090 |
Why?
| | Wound Infection | 1 | 2013 | 60 | 0.090 |
Why?
| | Registries | 4 | 2026 | 2400 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 102 | 0.090 |
Why?
| | Cellular Structures | 1 | 2011 | 6 | 0.090 |
Why?
| | Comorbidity | 1 | 2016 | 1665 | 0.090 |
Why?
| | Drug Therapy, Combination | 3 | 2021 | 1036 | 0.080 |
Why?
| | Microbial Viability | 1 | 2011 | 83 | 0.080 |
Why?
| | Extracellular Space | 1 | 2011 | 118 | 0.080 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 704 | 0.080 |
Why?
| | Patient Admission | 1 | 2012 | 216 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2013 | 585 | 0.080 |
Why?
| | Infant | 1 | 2024 | 10114 | 0.080 |
Why?
| | Survival Rate | 2 | 2018 | 2092 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5899 | 0.070 |
Why?
| | Blood Group Antigens | 1 | 2009 | 15 | 0.070 |
Why?
| | Sex Factors | 2 | 2026 | 2107 | 0.070 |
Why?
| | Incidence | 2 | 2026 | 2936 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2219 | 0.070 |
Why?
| | Aged | 5 | 2024 | 26432 | 0.070 |
Why?
| | Mucus | 1 | 2009 | 75 | 0.070 |
Why?
| | Mass Screening | 1 | 2016 | 1307 | 0.070 |
Why?
| | Inpatients | 1 | 2012 | 540 | 0.070 |
Why?
| | ADP Ribose Transferases | 1 | 2007 | 9 | 0.070 |
Why?
| | Burns | 1 | 2013 | 365 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 16 | 0.070 |
Why?
| | Furin | 1 | 2007 | 12 | 0.070 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2007 | 17 | 0.060 |
Why?
| | Cyclic GMP | 1 | 2007 | 88 | 0.060 |
Why?
| | Time Factors | 3 | 2024 | 7109 | 0.060 |
Why?
| | Bacterial Toxins | 1 | 2007 | 110 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2599 | 0.060 |
Why?
| | Phenotype | 1 | 2015 | 3206 | 0.060 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 190 | 0.060 |
Why?
| | Thiazolidines | 1 | 2026 | 13 | 0.060 |
Why?
| | Sulfones | 1 | 2007 | 127 | 0.060 |
Why?
| | Survivors | 1 | 2010 | 526 | 0.060 |
Why?
| | Oxadiazoles | 1 | 2026 | 33 | 0.060 |
Why?
| | Respiratory System | 1 | 2007 | 150 | 0.060 |
Why?
| | Transduction, Genetic | 1 | 2026 | 129 | 0.060 |
Why?
| | Transgenes | 1 | 2026 | 178 | 0.060 |
Why?
| | Rats | 2 | 2026 | 5586 | 0.060 |
Why?
| | Rats, Inbred F344 | 1 | 2026 | 266 | 0.060 |
Why?
| | Actigraphy | 1 | 2026 | 148 | 0.050 |
Why?
| | Quinoxalines | 1 | 2025 | 65 | 0.050 |
Why?
| | Pulse Wave Analysis | 1 | 2026 | 268 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2026 | 327 | 0.050 |
Why?
| | European Union | 1 | 2024 | 13 | 0.050 |
Why?
| | Piperazines | 1 | 2007 | 368 | 0.050 |
Why?
| | Respiration, Artificial | 1 | 2009 | 711 | 0.050 |
Why?
| | Developing Countries | 1 | 2026 | 312 | 0.050 |
Why?
| | Logistic Models | 2 | 2019 | 2126 | 0.050 |
Why?
| | Standard of Care | 1 | 2024 | 81 | 0.050 |
Why?
| | Reproductive Health Services | 1 | 2023 | 23 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 208 | 0.050 |
Why?
| | Nose | 1 | 2023 | 67 | 0.050 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2024 | 61 | 0.050 |
Why?
| | Cell Separation | 2 | 2016 | 300 | 0.050 |
Why?
| | Deoxyribonuclease I | 1 | 2022 | 42 | 0.050 |
Why?
| | Vasodilation | 1 | 2026 | 519 | 0.050 |
Why?
| | Saline Solution, Hypertonic | 1 | 2022 | 43 | 0.050 |
Why?
| | Rare Diseases | 1 | 2023 | 117 | 0.050 |
Why?
| | Social Class | 1 | 2024 | 260 | 0.040 |
Why?
| | Sex Education | 1 | 2022 | 33 | 0.040 |
Why?
| | Hot Flashes | 1 | 2023 | 92 | 0.040 |
Why?
| | Contraceptive Agents | 1 | 2022 | 65 | 0.040 |
Why?
| | Psychometrics | 1 | 2026 | 712 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 2 | 2014 | 367 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2026 | 1135 | 0.040 |
Why?
| | Iron | 1 | 2024 | 359 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2024 | 322 | 0.040 |
Why?
| | Nutritional Status | 1 | 2023 | 346 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2240 | 0.040 |
Why?
| | Biofilms | 2 | 2014 | 288 | 0.040 |
Why?
| | Genetic Counseling | 1 | 2021 | 82 | 0.040 |
Why?
| | Attitude | 1 | 2022 | 253 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2024 | 317 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 907 | 0.040 |
Why?
| | Longevity | 1 | 2021 | 179 | 0.040 |
Why?
| | Menopause | 1 | 2023 | 328 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2026 | 952 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2022 | 1361 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2022 | 771 | 0.040 |
Why?
| | Tetraspanin 30 | 1 | 2018 | 11 | 0.040 |
Why?
| | Ecosystem | 1 | 2023 | 483 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 172 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2023 | 628 | 0.030 |
Why?
| | British Columbia | 1 | 2018 | 27 | 0.030 |
Why?
| | Genetic Testing | 1 | 2021 | 492 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2012 | 2623 | 0.030 |
Why?
| | trans-Golgi Network | 2 | 2007 | 15 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2016 | 3647 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2026 | 3416 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2024 | 733 | 0.030 |
Why?
| | Gene Deletion | 1 | 2018 | 385 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2007 | 162 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 319 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2016 | 41 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2018 | 4118 | 0.030 |
Why?
| | Genetic Variation | 1 | 2021 | 996 | 0.030 |
Why?
| | Leadership | 1 | 2020 | 414 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 201 | 0.030 |
Why?
| | Medication Adherence | 1 | 2018 | 535 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4595 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2023 | 1408 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 77 | 0.030 |
Why?
| | Depression | 1 | 2024 | 1575 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 970 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1077 | 0.020 |
Why?
| | Survival Analysis | 1 | 2016 | 1378 | 0.020 |
Why?
| | Ciprofloxacin | 1 | 2013 | 31 | 0.020 |
Why?
| | Cohort Studies | 1 | 2023 | 6077 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1543 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 334 | 0.020 |
Why?
| | Superoxides | 1 | 2013 | 198 | 0.020 |
Why?
| | Drug Synergism | 1 | 2013 | 354 | 0.020 |
Why?
| | Cell Line | 2 | 2007 | 2814 | 0.020 |
Why?
| | Suspensions | 1 | 2011 | 28 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2012 | 212 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 447 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 399 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 382 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 558 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 8391 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2113 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2007 | 79 | 0.020 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2007 | 23 | 0.020 |
Why?
| | Guanylate Cyclase | 1 | 2007 | 36 | 0.020 |
Why?
| | Epithelial Sodium Channels | 1 | 2007 | 22 | 0.020 |
Why?
| | Insulin Infusion Systems | 1 | 2012 | 488 | 0.020 |
Why?
| | Sodium | 1 | 2007 | 196 | 0.010 |
Why?
| | Purines | 1 | 2007 | 188 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 534 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2007 | 1041 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 467 | 0.010 |
Why?
| | Mice | 2 | 2013 | 18297 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2012 | 1412 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2007 | 883 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4580 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2134 | 0.010 |
Why?
| | Insulin | 1 | 2012 | 2525 | 0.010 |
Why?
| | Macrophages | 1 | 2007 | 1532 | 0.010 |
Why?
| | Signal Transduction | 1 | 2007 | 5246 | 0.010 |
Why?
|
|
Taylor-Cousar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|